Abstract
Introduction: It has recently been shown that late follicular phase progesterone levels correlate well with those in the early luteal phase, and that progesterone levels before and 12 h after human chorionic gonadotropin (hCG) administration predict levels during the early luteal phase. This study investigated determinants of serum hCG levels after a bolus dose of hCG for triggering ovulation in women undergoing in vitro fertilization (IVF).Materials and Methods: This retrospective analysis was performed on data from a prospective study of women aged 18–42 years with normal ovarian reserve receiving gonadotropin-releasing hormone (GnRH) antagonist co-treatment during ovarian stimulation with follicle-stimulating hormone (FSH) who were followed until 6 days after oocyte pick-up (OPU) in a single IVF cycle. The main outcome measures were early luteal phase serum hCG levels, and predictors of those levels.Results: There was wide inter-individual variability in early phase hCG concentrations over the period from 12 h after hCG injection up to 6 days after OPU. Patients with serum hCG values in the bottom 10% had a significantly higher body mass index (BMI; p = 0.038) and a significantly longer duration of stimulation (p = 0.014) than those with higher serum hCG values. Serum progesterone levels up to the first 36 h after hCG injection were significantly higher in the low vs. higher serum hCG group, but were similar at all other time points. There was a significant correlation between serum hCG level after hCG administration and BMI (lower BMI = higher serum hCG). In a cluster analysis, patients with the lowest serum hCG and progesterone levels at 12 h after hCG injection had significantly higher BMI, and significantly lower anti-Müllerian hormone level, duration of stimulation, and number of follicles of ≥11 and ≥14 mm compared with the other three clusters.Conclusion: Predictors of low serum hCG after a trigger bolus were difficult to determine, but BMI seems to be important. More detailed information on the luteal phase hormonal profile and data on predictors of hormone levels during this critical period can facilitate the development of strategies to allow individualization of the luteal phase support regimen, potentially improving IVF outcomes.
Highlights
It has recently been shown that late follicular phase progesterone levels correlate well with those in the early luteal phase, and that progesterone levels before and 12 h after human chorionic gonadotropin administration predict levels during the early luteal phase
Human chorionic gonadotropin is the gold standard treatment for inducing final maturation of follicles during a variety of infertility treatment modalities [1]. This hormone acts as a surrogate for the mid-cycle luteinizing hormone (LH) surge in natural cycles, triggering final maturation of oocytes and ovulation, and stimulating the corpus luteum to secrete progesterone to improve endometrial receptivity [2]
Serum progesterone levels up to the first 36 h after Human chorionic gonadotropin (hCG) injection were significantly higher in the low vs. higher serum hCG group, but were similar at all other time points (Table 3)
Summary
It has recently been shown that late follicular phase progesterone levels correlate well with those in the early luteal phase, and that progesterone levels before and 12 h after human chorionic gonadotropin (hCG) administration predict levels during the early luteal phase. Human chorionic gonadotropin (hCG) is the gold standard treatment for inducing final maturation of follicles during a variety of infertility treatment modalities [1]. This hormone acts as a surrogate for the mid-cycle luteinizing hormone (LH) surge in natural cycles, triggering final maturation of oocytes and ovulation, and stimulating the corpus luteum to secrete progesterone to improve endometrial receptivity [2]. The study that provided pharmacokinetic data for the registration of recombinant hCG (r-hCG) showed a relatively uniform profile for up to 12 days after administration of a single 5,000 IU subcutaneous dose in healthy male and female volunteers [3]. The authors suggested that this may have been due to differences in the body mass index between the patients (18.9 and 24.0 kg/m2); there was a 10-year age difference between the subjects (22 vs. 32 years) [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
